Department of Otolaryngology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Clin Cancer Res. 2010 Feb 1;16(3):857-66. doi: 10.1158/1078-0432.CCR-09-2604. Epub 2010 Jan 26.
This study aims to investigate the role of the aberrant expression of Transkelolase-like 1 (TKTL1) in head and neck squamous cell carcinoma (HNSCC) tumorigenesis and to characterize TKTL1 contribution to HNSCC tumorigenesis through aerobic glycolysis and HIF1alpha stabilization.
TKTL1 promoter hypomethylation and mRNA/protein aberrant expression were studied in human HNSCC tumor samples and normal mucosas. Oncogenic functions of TKTL1 were examined in HNSCC cell line panels and tumor xenograft models with TKTL1 expression construct. The metabolite levels of fructose-6-phosphate, glyceraldehydes-3-phosphate, pyruvate, lactate, and the levels of HIF1alpha protein and its downsteam glycolytic targets were compared between the TKTL1-expressing and vehicle-expressing HNSCC cells. Meanwhile, the effects of HIF1alpha/glycolytic inhibitors were evaluated on the TKTL1 transfectants.
TKTL1 exhibits high frequency of promoter hypomethylation in HNSCC tumors compared with the normal mucosas, correlating with its overexpression in HNSCC. Overexpression of TKTL1 in HNSCC cells promoted cellular proliferation and enhanced tumor growth in vitro and in vivo. Overexpression of TKTL1 increased the production of fructose-6-phosphate and glyceraldehyde-3-phosphate, in turn elevating the production of pyruvate and lactate, resulting in the normoxic stabilization of the malignancy-promoting transcription factor HIF1alpha and the upregulation of downstream glycolytic enzymes. Notably, the reduction of TKTL1 expression decreased HIF1alpha accumulation and inhibition with HIF1alpha and/or the glycolysis inhibitor could abrogate the growth effects mediated by TKTL1 overexpression.
TKTL1 is a novel candidate oncogene that is epigenetically activated by aberrant hypomethlation and contributes to a malignant phenotype through altered glycolytic metabolism and HIF1alpha accumulation.
本研究旨在探讨转酮醇酶样 1(TKTL1)异常表达在头颈部鳞状细胞癌(HNSCC)肿瘤发生中的作用,并通过有氧糖酵解和 HIF1α稳定来描述 TKTL1 对 HNSCC 肿瘤发生的贡献。
研究了人 HNSCC 肿瘤样本和正常黏膜中 TKTL1 启动子低甲基化和 mRNA/蛋白异常表达。在 HNSCC 细胞系面板和肿瘤异种移植模型中,通过 TKTL1 表达构建体检测 TKTL1 的致癌功能。比较了 TKTL1 表达和载体表达的 HNSCC 细胞之间果糖-6-磷酸、甘油醛-3-磷酸、丙酮酸、乳酸的代谢物水平以及 HIF1α 蛋白及其下游糖酵解靶标的水平。同时,评估了 HIF1α/糖酵解抑制剂对 TKTL1 转染子的影响。
与正常黏膜相比,HNSCC 肿瘤中 TKTL1 表现出高频启动子低甲基化,与其在 HNSCC 中的过表达相关。TKTL1 在 HNSCC 细胞中的过表达促进了细胞增殖,并增强了体外和体内的肿瘤生长。TKTL1 的过表达增加了果糖-6-磷酸和甘油醛-3-磷酸的产生,进而增加了丙酮酸和乳酸的产生,导致促进恶性的转录因子 HIF1α 在常氧条件下的稳定和下游糖酵解酶的上调。值得注意的是,降低 TKTL1 表达可减少 HIF1α 的积累,抑制 HIF1α 和/或糖酵解抑制剂可消除由 TKTL1 过表达介导的生长效应。
TKTL1 是一种新的候选癌基因,通过异常低甲基化被激活,通过改变糖酵解代谢和 HIF1α 积累促进恶性表型。